MAP Migraine Drug Meets Late-Stage Study Goals
Tue, 05/26/2009 - 5:38am
MOUNTAIN VIEW, Calif. (AP) — MAP Pharmaceuticals Inc. has announced that its migraine treatment candidate met all of its main goals in a late-stage study, including a reduction in pain. The drug candidate, called Levadex, is aimed at relieving pain and other symptoms associated with migraines. The drug is being developed as an orally inhaled treatment.